当前位置: 首页 >> 检索结果
943. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
作者: Rolf Olsson.;Kirsten M Boberg.;Ove Schaffalitsky de Muckadell.;Stefan Lindgren.;Rolf Hultcrantz.;Geir Folvik.;Helge Bell.;Magnhild Gangsøy-Kristiansen.;Jon Matre.;Andreas Rydning.;Ola Wikman.;Ake Danielsson.;Hanna Sandberg-Gertzén.;Kjell-Arne Ung.;Anders Eriksson.;Lars Lööf.;Hanne Prytz.;Hanns-Ulrich Marschall.;Ulrika Broomé.
来源: Gastroenterology. 2005年129卷5期1464-72页
There is no medical treatment of proven benefit for primary sclerosing cholangitis. This study aimed at studying the effect of a higher dose of ursodeoxycholic acid than previously used on survival, symptoms, biochemistry, and quality of life in this disease.
944. Effect of peptide YY3-36 on food intake in humans.
作者: Lukas Degen.;Sibylle Oesch.;Michel Casanova.;Stefanie Graf.;Silvia Ketterer.;Juergen Drewe.;Christoph Beglinger.
来源: Gastroenterology. 2005年129卷5期1430-6页
Studies in animals and humans suggest a role for peptide YY (PYY3-36) in regulating satiety. The physiologic role of PYY3-36, however, has not been investigated in detail.
945. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
作者: Ruggiero Francavilla.;Elena Lionetti.;Stefania Paola Castellaneta.;Anna Maria Magistà.;Giuseppe Boscarelli.;Domenico Piscitelli.;Annacinzia Amoruso.;Alfredo Di Leo.;Vito Leonardo Miniello.;Antonio Francavilla.;Luciano Cavallo.;Enzo Ierardi.
来源: Gastroenterology. 2005年129卷5期1414-9页
The currently recommended first-line eradication treatment of Helicobacter pylori in children is usually successful in about 75%. Recently, in adults, a novel 10-day sequential treatment has achieved an eradication rate of 95%. The aim of the study was to assess the H pylori eradication rate of the sequential treatment regimen compared with conventional triple therapy in children.
946. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
作者: Ting-Tsung Chang.;Robert G Gish.;Stephanos J Hadziyannis.;Janusz Cianciara.;Mario Rizzetto.;Eugene R Schiff.;Giuseppe Pastore.;Bruce R Bacon.;Thierry Poynard.;Shobha Joshi.;Kenneth S Klesczewski.;Alexandra Thiry.;Ronald E Rose.;Richard J Colonno.;Robert G Hindes.; .
来源: Gastroenterology. 2005年129卷4期1198-209页
Entecavir is a nucleoside analogue with potent in vitro activity against lamivudine-resistant hepatitis B virus (HBV). This randomized, dose-ranging, phase 2 study compared the efficacy and safety of entecavir with lamivudine in lamivudine-refractory patients.
947. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
作者: Ali Gur.;Bünyamin Dikici.;Kemal Nas.;Mehmet Bosnak.;Kenan Haspolat.;Aysegul Jale Sarac.
来源: BMC Gastroenterol. 2005年5卷30页
Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha.
948. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
作者: George Alexander.;Chalamalasetty S Baba.;Kamal Chetri.;T S Negi.;Gourdas Choudhuri.
来源: BMC Gastroenterol. 2005年5卷29页
The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of Lamivudine on HBeAg loss and seroconversion rates in Indian patients of CHB in relation to frequency, predictors and durability.
949. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy.
Treatment of intrahepatic cholestasis of pregnancy with ursodeoxycholic acid appears promising, but data are limited so far. The aim of this randomized study was to evaluate the efficacy and safety of ursodeoxycholic acid in comparison with cholestyramine.
950. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.
作者: Paul J Limburg.;Wenqiang Wei.;Dennis J Ahnen.;Youlin Qiao.;Ernest T Hawk.;Guoqing Wang.;Carol A Giffen.;Guiqi Wang.;Mark J Roth.;Ning Lu.;Edward L Korn.;Yurong Ma.;Kathleen L Caldwell.;Zheiwei Dong.;Philip R Taylor.;Sanford M Dawsey.
来源: Gastroenterology. 2005年129卷3期863-73页
Esophageal squamous cell carcinoma remains a leading cause of cancer death worldwide. Squamous dysplasia, the accepted histological precursor for esophageal squamous cell carcinoma, represents a potentially modifiable intermediate end point for chemoprevention trials in high-risk populations.
951. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
作者: Stefan Schreiber.;Paul Rutgeerts.;Richard N Fedorak.;Munaa Khaliq-Kareemi.;Michael A Kamm.;Michel Boivin.;Charles N Bernstein.;Michael Staun.;Ole Østergaard Thomsen.;Alison Innes.; .
来源: Gastroenterology. 2005年129卷3期807-18页
To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti-tumor necrosis factor, CDP870) in Crohn's disease.
952. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
作者: Ching-Lung Lai.;Nancy Leung.;Eng-Kiong Teo.;Myron Tong.;Florence Wong.;Hie-Won Hann.;Steven Han.;Thierry Poynard.;Maureen Myers.;George Chao.;Deborah Lloyd.;Nathaniel A Brown.; .
来源: Gastroenterology. 2005年129卷2期528-36页
A previous 4-week trial of telbivudine in patients with chronic hepatitis B indicated marked antiviral effects with good tolerability, leading to the present 1-year phase 2b trial.
953. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
作者: Michael von Wagner.;Miriam Huber.;Thomas Berg.;Holger Hinrichsen.;Jens Rasenack.;Tobias Heintges.;Alexandra Bergk.;Christine Bernsmeier.;Dieter Häussinger.;Eva Herrmann.;Stefan Zeuzem.
来源: Gastroenterology. 2005年129卷2期522-7页
Standard therapy of patients with chronic hepatitis C virus (HCV) infected with HCV genotype-2 or -3 is the combination of pegylated interferon-alpha and ribavirin for 24 weeks. Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rates is unknown.
954. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
作者: Hanns-Ulrich Marschall.;Martin Wagner.;Gernot Zollner.;Peter Fickert.;Ulf Diczfalusy.;Judith Gumhold.;Dagmar Silbert.;Andrea Fuchsbichler.;Lisbet Benthin.;Rosita Grundström.;Ulf Gustafsson.;Staffan Sahlin.;Curt Einarsson.;Michael Trauner.
来源: Gastroenterology. 2005年129卷2期476-85页
Rifampicin (RIFA) and ursodeoxycholic acid (UDCA) improve symptoms and biochemical markers of liver injury in cholestatic liver diseases by largely unknown mechanisms. We aimed to study the molecular mechanisms of action of these drugs in humans.
955. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.
作者: Shuichiro Shiina.;Takuma Teratani.;Shuntaro Obi.;Shinpei Sato.;Ryosuke Tateishi.;Tomonori Fujishima.;Takashi Ishikawa.;Yukihiro Koike.;Haruhiko Yoshida.;Takao Kawabe.;Masao Omata.
来源: Gastroenterology. 2005年129卷1期122-30页
Percutaneous radiofrequency ablation is a recently introduced treatment for hepatocellular carcinoma, whereas ethanol injection is now a standard therapy. We compared their long-term outcomes.
956. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation.
作者: Giuseppe Chiarioni.;Lara Salandini.;William E Whitehead.
来源: Gastroenterology. 2005年129卷1期86-97页
Biofeedback is reported to be as effective for slow transit constipation as for pelvic floor dyssynergia and no more effective than education. We aimed to test the hypothesis that biofeedback benefits only patients with pelvic floor dyssynergia, describe the physiologic mechanism of treatment, and identify predictors of success.
957. Colorectal cancer in patients under close colonoscopic surveillance.
作者: Douglas J Robertson.;E Robert Greenberg.;Michael Beach.;Robert S Sandler.;Dennis Ahnen.;Robert W Haile.;Carol A Burke.;Dale C Snover.;Robert S Bresalier.;Gail McKeown-Eyssen.;Jack S Mandel.;John H Bond.;Rosalind U Van Stolk.;Robert W Summers.;Richard Rothstein.;Timothy R Church.;Bernard F Cole.;Tim Byers.;Leila Mott.;John A Baron.
来源: Gastroenterology. 2005年129卷1期34-41页
Colonoscopic polypectomy is considered effective for preventing colorectal cancer (CRC), but the incidence of cancer in patients under colonoscopic surveillance has rarely been investigated. We determined the incidence of CRC in patients under colonoscopic surveillance and examined the circumstances and risk factors for CRC and adenoma with high-grade dysplasia.
958. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
作者: Vlad Ratziu.;Frédéric Charlotte.;Agnès Heurtier.;Sophie Gombert.;Philippe Giral.;Eric Bruckert.;André Grimaldi.;Frédérique Capron.;Thierry Poynard.; .
来源: Gastroenterology. 2005年128卷7期1898-906页
In nonalcoholic fatty liver disease (NAFLD), the distinction between steatosis and steatohepatitis (NASH) and the assessment of the severity of the disease rely on liver histology alone. The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH.
959. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
作者: Joseph J Y Sung.;May-Ling Wong.;Scott Bowden.;Choong-Tsek Liew.;Alex Y Hui.;Vincent W S Wong.;Nancy W Y Leung.;Stephen Locarnini.;Henry L Y Chan.
来源: Gastroenterology. 2005年128卷7期1890-7页
This study aimed to determine whether intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA and total HBV DNA levels at the end of therapy would predict sustained response to therapy.
960. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.
作者: Marc Lémann.;Jean-Yves Mary.;Jean-Frédéric Colombel.;Bernard Duclos.;Jean-Claude Soule.;Eric Lerebours.;Robert Modigliani.;Yoram Bouhnik.; .
来源: Gastroenterology. 2005年128卷7期1812-8页
An open study reported that patients with Crohn's disease in remission who have taken azathioprine for longer than 3.5 years are at low risk of relapse when azathioprine is discontinued. To confirm this observation, we performed a multicenter, double-blind, noninferiority withdrawal study.
|